Protalix (PLX) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
Good morning, esteemed guests, and welcome to Protalix BioTherapeutics Second Quarter 2026 financial and business results conference call. Please allow me to introduce our hosts, Mike Moyer of LifeSci Advisors, and our executives, Dror Bashan, President and CEO, and Gilad Mamlok, Senior Vice President and CFO. A press release detailing today's earnings and corporate updates is now available on our website.
Please take a moment to review the disclaimer regarding forward-looking statements, as our remarks contain such statements. These statements are subject to various risks and uncertainties that may lead to actual results differing materially from the projections made.
Turning over to Dror Bashan, President and CEO, he expresses confidence in the company's outlook, attributing strength to profitable commercial partnerships. He highlights Elfabrio sales through Chiesi as a key driver in Q2 2026, with continued growth in revenues and a strong global penetration of Elfabrio. The company anticipates reaching approximately $3.2 billion in revenue by 2031, with Elfabrio capturing a market share of 15% to 20%.
Dror also emphasizes the potential of PRX-115, a long-acting uricase, which could significantly improve the quality of life for patients with uncontrolled gout and become a significant revenue driver in the future.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Protalix (PLX) Q2 2026 Earnings Call Transcript fool.com
- Protalix (PLX) Q2 2026 Earnings Call Transcript finance.yahoo.com
